🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In patients with mHSPC #prostatecancer randomized ph2 trial👉adding Lutetium-177 (Pluvicto) to docetaxel met primary end point👉significantly improved undetectable PSA at 48 weeks Outstanding talk by Arun Azad Congrats Arun, Michael Hofman ESMO - Eur. Oncology #ESMO24 OncoAlert UroToday.com

Inspirational presidential address from Howard Sandler on well-being, burnout, and patient outcomes at #ASTRO24 #radonc Pearls of wisdom: 1. Please correctly use sig figs 2. Know your walk-up music 3. Be careful with using the phrase “gold standard” ASTRO Cancer at Cedars-Sinai

Thank you Felix Feng for your contributions to the field of #prostatecancer research! Your innovative work leveraging artificial intelligence and molecular biomarkers is paving the way for better outcomes for patients everywhere. We are grateful for your leadership!

Thank you to all who attended #PCFRetreat23! It was truly our best conference ever with old & new friends and exciting cutting edge #ProstateCancer and other research presented. We hope everyone had a safe trip home & thank you for attending! Prostate Cancer Foundation UroToday.com

This is what it is all about. Raising $$ to fund the next and the next generation of cancer researchers. Thank you to the Conquer Cancer, the ASCO Foundation Board ASCO for making this a priority. Inspired to hear from the supported researchers +Lucky Lara for you fantastic keynote

From inspirational speakers to in-person learning and brainstorming, the 2024 Grants and Awards Scientific and Career Development Retreat was a great success! Thanks to all attendees and board members who traveled to be together and share their knowledge at ASCO HQ!

Tower Cancer Research Foundation is pleased to announce the 2024 Career Development Grant Award Recipients! We'll be profiling each recipient and their research in the coming weeks, so stay tuned. Congratulations to all! #careerdevelopmentawards #towercancer #tcrf #research

Tower Cancer Research Foundation Congrats Anthony T. Nguyen, MD, PhD Cancer at Cedars-Sinai on this significant milestone

Our very own Cedars-Sinai Edwin Posadas, MD w/insightful discussant session ➡️ can we definitely say who can benefit from RT vs RP in #high-risk #pcsm? Not yet but imp of multi-D care. Molecular info like #PORTOS can help optimize selection/dosing of RT ASCO #GU25 OncoAlert

🎉 Congratulations to Anthony Nguyen, MD, PhD, of Cedars-Sinai Medical Center, one of Tower Cancer Research Foundation’s 2024 Career Development Grant recipients! 🎉 Read the full abstract of his work online: ow.ly/NYrf50V9Ic2 #TowerCancerResearch #CareerDevelopmentGrant

Congrats Anthony T. Nguyen, MD, PhD!!

Congrats Anthony! We are so lucky to have you at Cancer at Cedars-Sinai

What an honor to welcome 2021 Nobel Prize winner Ardem Patapoutian from Scripps Research to Cedars-Sinai Research Day XIII. Standing room only talk. Ardem Patapoutian showing his tattoo of PIEZO1/2 pressure sensor strategically on his arm to open with bicep curling. Cedars-Sinai Academic Medicine Cancer at Cedars-Sinai

Inspiring start to Cedars-Sinai Academic Medicine academic retreat by Shlomo Melmed, MD, who emphasizes how our unique structure enables progress towards science-based clinical innovation.

Dr. Anthony Nguyen Anthony T. Nguyen, MD, PhD is one of the recipients of the Tower Cancer Research Foundation 2024 Career Development Grant! Dr. Nguyen was awarded for his project “Targeting Myeloid Inflammation to Reprogram the Immunosuppressive Microenvironment of #ProstateCancer.” towercancer.org/member/anthony…

🔬The Cancer at Cedars-Sinai GU oncology Disease Research Group had a retreat to... 💡Generate new ideas 🤝Plan collaborations 💁‍♂️Share experiences ⭐️Lots of great things to come! Prostate Cancer Foundation UroToday.com Department of Surgery at Cedars-Sinai Cedars-Sinai Academic Medicine Cedars-Sinai

Praful Ravi #ICECAP meta-analysis shows addition of docetaxel to RT + long-term ADT in high-risk localized #prostatecancer does not significantly improve OS and MFS, modest benefits in EFS/PCSM #ASCO25 OncoAlert

PhII rand Metacure trial of oligo #mCSPC SBRT to all mets + ADT + apa +/- abi ➡️ PSA0 w/T recovery (primary endpt) met with 42% with short ADT + apa and 50% w/short course ADT + apa and combined group with abi #ASCO25 OncoAlert

Dr. Sandhu rand PhII #IIT EVOLUTION of LuPSMA +/- nivo/ipi #PSMA+ #mCRPC (must have prior ARPI) ➡️ closed due to 4 cases of myocarditis (1 G5). rPFS 12 mos vs 8.5 mos, ORR 71% vs 50% in combination arm #ASCO25 OncoAlert

Phase 3 of novel viral vector in #prostatecancer pts getting XRT. Intermediate to high-risk. Despite slide title - only helps w/o ADT but not w/ADT. Curves separate at 24 mos when biopsies done. Unlikely to help high risk w/ADT but may replace ADT for intermediate risk? #ASCO25